Posts by Sandra Ansanay-Alex
FinalSpark’s Neuroplatform: the era of organic computing has begun!
Swiss startup FinalSpark has just launched its Neuroplatform, the world’s first commercial bioprocessor. This innovation promises to be a technological and energy revolution, with the potential to disrupt the field of artificial intelligence FinalSpark’s Neuroplatform: A Radical Approach What makes FinalSpark’s research groundbreaking is the fact that FinalSpark lab is fully accessible remotely, as…
Read MoreLymphatica Medtech Closes € 17.9 M Series B Funding Round
Lymphatica Medtech SA, a clinical-stage company based in Lausanne, Switzerland, specialized in innovative treatments for lymphedema, has raised €17.9 million in Series B funding. This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions…
Read MoreNovostia Secures Additional CHF 5.6 million in Funding and Announces New CEO
Novostia, a Biopôle-based pioneering medical technology company, specializing in the development of a disruptive heart valve prosthesis, at clinical stage, today announces a leadership transition alongside the successful completion of a CHF 5.6 million fund raise to further accelerate the company’s development efforts and advance its clinical evidence base. Appointment of New CEO…
Read MoreSilvia Scherer, from APTISSEN SA, is Entrepreneur of the Year
On 4 October 2024, Silvia Sherer, co-founder of APTISSEN, became Swiss Entrepreneur of the Year in the category Industry, High-Tech & Life Sciences during a ceremony in Lucerne. Aptissen SA is a Geneva-based biomedical company specializing in the development and commercialization of innovative medical devices, primarily focused on treating osteoarticular conditions, such as…
Read MoreAtinary Technologies Announces Strategic Collaboration with Snapdragon Chemistry
Atinary Technologies has joined forces with Snapdragon Chemistry, a Cambrex subsidiary, to bring AI-driven automation into pharmaceutical process development By integrating Atinary’s no-code AI platform, SDLabs™, and Snapdragon’s LabOS™ software, the partnership has developed an automated Solid-Phase Oligonucleotide Synthesizer (SPOS), designed to optimize drug synthesis processes autonomously. This collaboration aims to improve efficiency…
Read MoreSIB inaugurates its Centre for Pathogen Bioinformatics
SIB has launched a new Centre for Pathogen Bioinformatics, building on its contributions during the COVID-19 pandemic. The Centre will offer expertise and services in computational pathogen research and surveillance to Swiss federal authorities and the global research community. The Centre for Pathogen Bioinformatics’s goal is to ensure Switzerland remains a leader in…
Read MoreActival Revolutionizes Dental Aligners with Innovative Microchannel Technology
Actival, a Neuchâtel-based startup supported by the CSEM (Swiss Center for Electronics and Microtechnology), is transforming the dental aligner market with its innovative “Active Aligners”. They incorporate patented 3D-printed microchannel technology, ensuring optimal oral hygiene throughout the treatment period. Microchannels for Better Hygiene Traditional aligners, while discreet and comfortable, have been linked to…
Read MoreSeprify SA & Xemperia, finalists of the IFF Prize
The State of Fribourg and BCF announce the nine finalists for the IFF Prize. 9 companies, out of 39 applications, have been selected. Two of them, Xemperia and Seprify, are promising start-ups of the Swiss Health Valley. Seprify SA: A white pigment derived from cellulose Seprify develops and produces plant-based ingredients to offer…
Read MoreFDA Clears Abionic’s IVD CAPSULE PSP for Early Detection of Sepsis
Abionic, a Vaud-based medical diagnostics company, announced that its IVD CAPSULE PSP test received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This test, designed for the early detection of sepsis, represents a major breakthrough in sepsis diagnostics by significantly reducing the time-to-detection, potentially improving patient outcomes. The FDA clearance marks an important…
Read MoreThe CHUV launches the Swiss BioMotion Lab
This laboratory, which specialises in the analysis and rehabilitation of movement, will enable large-scale research to be carried out and patients, particularly those suffering from osteoarthritis, to benefit from biomechanical data that until now has been used mainly in research. Osteoarthritis is the most common joint disease, marked by the progressive breakdown of…
Read More